ANTIHISTAMINE FOR USE IN TREATMENT OF BREAST CANCER

• US 20180008588A1
• Filed: 01/19/2016
• Published: 01/11/2018
• Est. Priority Date: 01/19/2015
• Status: Active Grant

• Current Assignee: Belina Pharma AB
• Original Assignee: Belina Pharma AB
• Inventors: OLSSON, Hakan, EINEFORS, Rickard
• Granted Patent: US 10,456,388 B2
• Time in Patent Office: Days
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/4515 having a butyrophenone group in position 1, e.g. haloperidol pipamperone A61K31/4545
• CPC Class Codes: A61K 31/4545 containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Disclosed herein is desloratadine or ebastin for use in treatment of a patient diagnosed with breast cancer. Also disclosed is desloratadine or ebastin for use in treatment of a patient diagnosed with a cancer type susceptible to immunotherapy.

Claims

1. A method of treating breast cancer in a patient, the method comprising administering to the patient an effective amount of desloratadine or ebastin.

2. The method of claim 1, wherein the breast cancer is selected from the group consisting of positive and negative ER, PR, her2 breast cancer molecular subtypes, and invasive breast carcinomas.

3. The method of claim 1, wherein the breast cancer is selected from the group consisting of positive and negative ER invasive breast carcinomas.

4. The method of claim 1, wherein the treatment is continuous for at least 50 days.

5. The method of claim 1, wherein said treatment seeks to improve the prognosis for the patient diagnosed with breast cancer.

6. The method of claim 1, wherein said treatment seeks to increase the survival time for the patient diagnosed with breast cancer.

7. The method of claim 1, wherein the daily dose of the desloratadine or ebastin corresponds to the defined daily dose (DDD).

8. The method of claim 1, wherein the dose of the desloratadine is between 2.5 to 45 mg per day.

9. The method of claim 1, wherein the dose of the desloratadine is between 45 to 250 mg per day.

10. The method of claim 1, wherein the dose of the ebastin is between 2.5 to 100 mg per day.

11. The method of claim 1, wherein the dose of the ebastin is between 100 to 500 mg per day.

12. The method of claim 1, wherein the patient is not diagnosed with a seasonal allergic condition.

13. The method of claim 1, wherein the patient is perioperational.

14. The method of claim 1, wherein the patient further is treated with radiotherapy, chemotherapy and/or hormonal treatment.

15. A method of treating cancer of a type susceptible to immunotherapy in a patient, the method comprising administering to the patient an effective amount of desloratadine or ebastin.